Matinas BioPharma Holdings Inc (MTNB) stock is up 41.56% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives MTNB stock a score of 67 out of a possible 100.
That rank is mainly influenced by a fundamental score of 95. In addition to the average rating from Wall Street analysts, MTNB stock has a mean target price of $2.48. This means analysts expect the stock to rise 127.52% over the next 12 months. MTNB's rank also includes a short-term technical score of 54. The long-term technical score for MTNB is 50.
MTNB has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on MTNB!
Matinas BioPharma Holdings Inc (MTNB) stock has fallen -7.63% while the S&P 500 is up 0.25% as of 10:42 AM on Wednesday, Sep 15. MTNB is down -$0.09 from the previous closing price of $1.18 on volume of 1,939,602 shares. Over the past year the S&P 500 has risen 30.96% while MTNB is up 41.56%. MTNB lost -$0.11 per share in the over the last 12 months.
Click Here to get the full Stock Report for Matinas BioPharma Holdings Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
